Success Stories: EB-1A Petition Approved for Research Associate from India in the Field of Cancer Research Whose Work Had Collected 121 Citations

Client’s Testimonial:

“I-140 is approved! Thanks much.”

On June 17^th, 2016, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Associate in the Field of Cancer Research (Approval Notice).

General Field: Cancer Research

Position at the Time of Case Filing: Research Associate

Country of Origin: India

Service Center: Texas Service Center (TSC)

State of Residence at the Time of Filing: Texas

Approval Notice Date: June 17^th, 2016

Processing Time: 13 months, 12 days (Premium Processing Requested)

Case Summary:

A gifted research associate working in the field of cancer research approached North America Immigration Law Group (NAILG) for help when she decided that she wanted to become an American permanent resident. Our client, whose work is focused on designing and evaluating drugs used to treat advanced prostate cancer, knew that we would work diligently to help her accomplish her goal of getting one step closer to a green card.

Highlighting our client’s credentials:

EB-1A is upheld by a very high standard of law and we had to prove that our client had risen to the top of the field and that her investigations are essential to the United States. We detailed her M.S. in Biotechnology, 7 peer-reviewed scientific articles, 1 book chapter, and numerous conference presentations. Leaving no stone unturned, we also listed the 121 citations gathered from her work and the 8 times she assessed the work of her peers for a handful of scientific journals. We left no room for doubt that our client deserved to have her EB-1A petition approved.

To further strengthen the case, we urged our client to gather recommendation letters from several of her peers. We needed other experts in the field to confirm the value of our client’s research not just to cancer researchers in the US, but also to those based around the world. To our delight, our client returned with six signed letters, all of which contained statements such as these:

“Breast cancer and prostate cancer are enormously widespread and pose serious health issues around the world and in the United States. Breast cancer is the most common type of cancer in women, while prostate cancer is the second leading type in men. […] While drug treatment can be effective, it often fails due to drug resistance, so finding new method to counteract the growth and spread of cancer is essential to halting its progress and reducing its impact. [Client’s] research is providing the answers we need. She is at the forefront of researchers doing this type of work, and I look forward to watching her string of discoveries continue.”

“It is clear that the work ethic and spirit of innovation that enabled [Client] to develop superior methods for the tanning industry are now being put to use in her work as a cancer researcher.”

The long road to the finish line:

It was a long and winding road to the EB-1A finish line. The first hurdle we encountered involved raising a service request on our client’s behalf after her case was considered outside the normal processing time. Because of the long wait, our client opted to upgrade her case to PP (which would have allowed action to be taken on her case within 15 days). However, the USCIS issued a request for evidence (RFE) a little over two weeks after her case was upgraded to PP. We promptly put together a response to the RFE and 2 weeks after the USCIS received it, they approved our client’s EB-1A petition. We wish her the best as she embarks on the final leg of the green card journey: filing an I-485 application.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.